BioSpace News Archive

Business

Takeda Pairs Up With BridGene to Solve “Undruggable” Neurodegenerative Diseases

The companies will harness BridGene’s IMTAC (Isobaric Mass Tagged Affinity Characterization) Chemoproteomics platform to identify targets and small molecule drug candidates.

March 30, 2021
·
2 min read
·
Alex Keown
Policy

Merck’s Busy Day: FDA Rejection, EU Recommendation and a Spinoff Sale

Merck is having a very busy week. Here’s today’s news.

March 30, 2021
·
3 min read
·
Mark Terry
Drug Development

Global Vaccine Passports Edge Closer, Speeding Arrival of the Next “Normal”

Vaccine passports are an interim step that can speed the return of some semblance of normality by allowing the rapidly growing numbers of vaccinated people to travel more easily and to attend typically crowded sporting events, concerts and religious services.

March 30, 2021
·
5 min read
·
Gail Dutton
Genetown

Omega Raises $126 Million to Unlock Potential of Epigenomic Controller Candidate

Omega Therapeutics secured $126 million in a Series C financing round that will be used to advance the company’s lead epigenomic controller candidate, OTX-2002, a potential treatment for hepatocellular carcinoma, as well as other next-generation pipeline assets.

March 30, 2021
·
2 min read
·
Alex Keown
$David Mdzinarishvili\TASS via Getty Images$

Genetown

BioNTech-Pfizer Increase COVID-19 Vaccine Output Target Again

With the ongoing global pandemic, BioNTech and Pfizer announced that they will be boosting their manufacturing capacity of the COVID-19 vaccine to 2.5 billion for 2021.

March 30, 2021
·
2 min read
·
Kristiane Polido
Business

After About 50 Years, the mRNA Revolution is Here

Between the Moderna and Pfizer-BioNTech COVID-19 vaccines, there are two mRNA therapeutics on the market … the only two.

March 30, 2021
·
4 min read
·
Mark Terry
Business

TCR2 Therapeutics Leases Manufacturing Space in Maryland, Autolus Backs Out of U.S. Expansion

After Autolus Therapeutics’ backed out of its plan to establish a manufacturing center in Rockville, Maryland, Massachusetts-based TCR2 Therapeutics has stepped up to the plate to build an 85,000 square-foot cell therapy manufacturing facility in Rockville.

March 30, 2021
·
3 min read
·
Alex Keown
Drug Development

Merck KGaA’s ATR Inhibitor Shows Promise in Both Cancer and COVID-19

A research collaboration among UCLA investigators and Merck KGaA, has pointed to the drug as showing promise for COVID-19. It is also being touted for its unusually broad effect in treating a range of cancers.

March 30, 2021
·
3 min read
·
Mark Terry
Drug Development

ALS Patients Fight for the Right to Try and Patient-Centric Trial Design

Lisa Stockman Mauriello was diagnosed with ALS in January and is seeking access to Biogen’s tofersen (BIIB067) through the Right to Try Act. Her case has reinvigorated the ALS community and its fight for expanded access to investigational therapies for this cruel, always fatal disease.

March 30, 2021
·
7 min read
·
Heather McKenzie
2021 Biopharma Update on the Novel Coronavirus: March 30

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2021.

March 30, 2021
·
3 min read
·
BioSpace Editorial Staff